Abstract
The human cytochrome P450 (CYP) enzyme CYP4Z1 is a fatty acid hydroxylase which among human CYPs is unique for being much stronger expressed in the mammary gland than in all other tissues. Moreover, it is strongly overexpressed in all subtypes of breast cancer, and some overexpression has also been found in other types of malignancies, such as ovarian, lung, and prostate cancers, respectively. Due to its unique expression pattern it is conceivable that this enzymes' activity might be exploited for a new therapeutic approach. However, the main challenge for a CYP4Z1-based prodrug strategy (CBPS) for the treatment of breast cancer (and possibly other CYP4Z1-positive malignancies) is the identification of candidate prodrugs that can be activated by this enzyme. In this mini-review we summarize the current knowledge about the enzymatic properties of the CYP4Z1 enzyme as well as on the expression pattern of the CYP4Z1 gene in both normal and cancer cells. Moreover, we present the first homology model of this enzyme and give an outlook on its potential use in cancer treatment strategies.
Keywords: Breast cancer, CYP4Z1, fatty acid hydroxylation, homology model, monooxygenase, prodrug.
Current Pharmaceutical Design
Title:CYP4Z1 – A Human Cytochrome P450 Enzyme that Might Hold the Key to Curing Breast Cancer
Volume: 23 Issue: 14
Author(s): Xu Yang, Michael Hutter, Wilson Wen Bin Goh and Matthias Bureik*
Affiliation:
- School of Pharmaceutical Science and Technology (SPST), Tianjin University, 92 Weijin Road, Nankai District, Tianjin 300072,China
Keywords: Breast cancer, CYP4Z1, fatty acid hydroxylation, homology model, monooxygenase, prodrug.
Abstract: The human cytochrome P450 (CYP) enzyme CYP4Z1 is a fatty acid hydroxylase which among human CYPs is unique for being much stronger expressed in the mammary gland than in all other tissues. Moreover, it is strongly overexpressed in all subtypes of breast cancer, and some overexpression has also been found in other types of malignancies, such as ovarian, lung, and prostate cancers, respectively. Due to its unique expression pattern it is conceivable that this enzymes' activity might be exploited for a new therapeutic approach. However, the main challenge for a CYP4Z1-based prodrug strategy (CBPS) for the treatment of breast cancer (and possibly other CYP4Z1-positive malignancies) is the identification of candidate prodrugs that can be activated by this enzyme. In this mini-review we summarize the current knowledge about the enzymatic properties of the CYP4Z1 enzyme as well as on the expression pattern of the CYP4Z1 gene in both normal and cancer cells. Moreover, we present the first homology model of this enzyme and give an outlook on its potential use in cancer treatment strategies.
Export Options
About this article
Cite this article as:
Yang Xu, Hutter Michael, Goh Wen Bin Wilson and Bureik Matthias*, CYP4Z1 – A Human Cytochrome P450 Enzyme that Might Hold the Key to Curing Breast Cancer, Current Pharmaceutical Design 2017; 23 (14) . https://dx.doi.org/10.2174/1381612823666170207150156
DOI https://dx.doi.org/10.2174/1381612823666170207150156 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel dibenzo[b,d]furan–1H-1,2,4-triazole derivatives: Synthesis and antitumor activity
Anti-Cancer Agents in Medicinal Chemistry Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors
Current Topics in Medicinal Chemistry Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Role of Estradiol and Progesterone in HIV Susceptibility and Disease Progression
Mini-Reviews in Medicinal Chemistry The Role of TNFSF15 in the Modulation of Neovascularization and Inflammation
Current Hypertension Reviews Analysis of TLC-Bioautography and TLC-Spot Visualization of <i>Atropa accuminata</i> and <i>Atropa belladonna</i> Extracts as Antioxidant and Antibacterial Agents Against Human Pathogenic Bacteria
Current Pharmaceutical Analysis Current Strategies in the Modification of PLGA-based Gene Delivery System
Current Medicinal Chemistry Understanding Nutritional Interventions and Physical Exercise in Non-Alcoholic Fatty Liver Disease
Current Molecular Medicine Paeonol, a Powerful Natural Product with Broad Biological Spectra by Inhibiting Inflammatory Pathway
Current Traditional Medicine Nanoparticle-Based Drugs: A Potential Armamentarium of Effective Anti-Cancer Therapies
Current Drug Metabolism APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Retraction Notice: The Benefits and Risks of Different Therapies in Preventing Postoperative Nausea and Vomiting in Patients Undergoing Thyroid Surgery
Current Drug Safety Can Systems Biology Understand Pathway Activation? Gene Expression Signatures as Surrogate Markers for Understanding the Complexity of Pathway Activation
Current Genomics Group-sparse Modeling Drug-kinase Networks for Predicting Combinatorial Drug Sensitivity in Cancer Cells
Current Bioinformatics Pharmaceutical Strategies Enhancing Cell Penetration Efficiencies of Non-Viral Gene Delivery Systems
Current Gene Therapy Application and Future Prospect of Extracellular Matrix Targeted Nanomaterials in Tumor Theranostics
Current Drug Targets Editorial: Alteration of Redox Equilibrium, Inflammation and Progression of Disease
Current Medicinal Chemistry Antidotal Effects of Curcumin Against Agents-Induced Cardiovascular Toxicity
Cardiovascular & Hematological Disorders-Drug Targets Estrogen Receptor-Positive and Estrogen Receptor-Negative Human Breast Cancer Cells: Regulation of Expression of Cancer-Related Genes by Estradiol and Tamoxifen
Current Signal Transduction Therapy Aberrant Expression of MicroRNAs in B-cell Lymphomas
MicroRNA